ERBB2 and hydrops fetalis: The large majority of evidence in the literature focuses on the application of neurohormonal therapies (e.g., angiotensin-converting enzyme inhibitors [ACEIs], angiotensin receptor blockers [ARBs], and beta-blockers) [98,99,100] in the prevention of LV dysfunction and HF in patients receiving anthracyclines or anti-HER2 agents.